Robert Edwards
Obstetrics & Gynecology · Pittsburgh, PANPI 1912970377
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,343 of the $35,888 with a category attached, or 98.5%. Merck accounts for 99.0% of it on its own, with 3 other manufacturers making up the rest. Among obstetrics & gynecology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 29 payments — averaging $1237.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$36K
- Aadi Bioscience, Inc.$204
- Corcept Therapeutics$120
- Johnson & Johnson$45
Across 15 payments — averaging $124,061 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.9M
What the payments were for
- Consulting fees$35,34398%
- Food & beverage$5351%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 25 | $35,519 |
| Aadi Bioscience, Inc. | 1 | $204 |
| Corcept Therapeutics | 1 | $120 |
| Johnson & Johnson | 2 | $45 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$35,888 in reported general payments places this provider in the 95th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 46 | $483,418 |
| EliquisApixaban | 13 | $10,754 |
| Anastrozole | 22 | $557 |
| Dexamethasone | 16 | $520 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $107 |
| Metformin Hcl | 20 | $38 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Pittsburgh
- Catherine ChappellPittsburgh$94K
- Suketu MansuriaPittsburgh$47K
- Sarah TaylorPittsburgh$29K
- Grace FergusonPittsburgh$20K
- Michele StrakaPittsburgh$20K
- Anita ShowalterPittsburgh$15K
- Ted LeePittsburgh$12K
- Eric LantzmanPittsburgh$11K
- Stephen KlaskoPhiladelphia$2.2M
- Stephanie SoberPhiladelphia$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.